Collegium's General Counsel Trims His Stake as the Company Doubles Down on ADHD

Executive VP & General Counsel Dieter David sold 6,224 shares for $228,110 on March 9, 2026 (a 6.40% trim of his direct stake under a 10b5-1 plan), leaving him with 91,047 shares valued at ~$3.39M. Collegium grew Jornay PM 48% in its first full year and is guiding Jornay to $190–$200M in 2026 (~31% growth) with total company revenue guidance of $805–$825M; the company announced a $650M acquisition of AZSTARYS ten days after the sale, underscoring an accelerating pivot into ADHD treatments.

Analysis

The company's strategic pivot from legacy pain assets toward neuropsychiatric indications changes the competitive set and margin profile more than most investors appreciate. ADHD franchises live and die on prescription persistence, pediatric/adolescent market access, and formulary placement—metrics that trade much more on commercial execution and managed-care negotiations than on traditional specialty pharmacy relationships that supported the opioid franchise.

Second-order supply and cost dynamics matter: shifting SKU mix from abuse‑deterrent, extended‑release opioid formulations to stimulant/non‑stimulant ADHD products will alter gross margin runway (different packaging, dosing conversion rates, and distribution channels) and may leave legacy contract-manufacturers underutilized unless capacity is reallocated or outsourced quickly. Additionally, any material M&A to accelerate the pivot increases sensitivity to near-term free cash flow and leverage, making upcoming guidance cadence and cash use the dominant short-term valuation drivers.

Key risks and catalysts are concentrated around commercial execution and regulatory/payer response rather than product science. In the near term (weeks–months) headline Rx trends, gross-to-net trajectory, and updated guidance will move the stock; over 6–18 months, integration success for acquired assets, formulary wins/losses, and potential legacy legal/regulatory developments will re-rate multiples. The bullish case requires sustained prescription growth and margin stabilization; the bearish case is execution failure leading to compressed multiples and potential dilutive financing needs.

Key Decisions for Investors

• Tactical long (defined-risk options): Buy the COLL 6–9 month call spread (buy nearer-term ATM call / sell out-of-the-money call ~30–40% above current spot) to capture upside from successful integration and continued RX momentum. Position size: 1–2% of portfolio; target 50–100% return if shares rally to the upper strike; max loss = premium paid.
• Event-driven long equity: Accumulate a small core position in the next 1–3 weeks ahead of the quarterly prescription/guidance print, scaling into weakness only if gross-to-net or organic prescription growth misses. Size to 2–3% portfolio as a staged build with stop-loss at a 15% drawdown from entry.
• Hedge/Pair trade: Pair long COLL with a short position in a large incumbent ADHD franchise (selective single-stock or sector ETF exposure) to isolate execution risk—reduce net beta while keeping exposure to successful product integration. Target neutral market exposure and tighten stop-loss on the short if sector-wide RX trends accelerate.
• Downside protection via options: If holding equity, buy 6–12 month protective puts at ~10–15% OTM to insure against an integration/cash-flow disappointment that historically compresses specialty pharma multiples. Cost should be sized so time decay is acceptable (<=1% portfolio for material protection).